Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA
Update: 2025-06-05
Description
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA.
In this episode, he discusses two papers: risk of MACE in patients with RA treated with JAKis compared to bDMARDs from the “JAK-pot” study, and the efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with RA and an inadequate response to MTX.
In this episode, he discusses two papers: risk of MACE in patients with RA treated with JAKis compared to bDMARDs from the “JAK-pot” study, and the efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with RA and an inadequate response to MTX.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
